Expert Point of View: Judy C. Boughey, MD

Get Permission

Error loading Partial View script (file: ~/Views/MacroPartials/TAP Article Portrait Widget.cshtml)

JUDY C. BOUGHEY, MD, a breast surgeon and clinical and translational researcher at the Mayo Clinic, Rochester, Minnesota, said the two studies highlight the importance of discussing genetic testing with patients who are diagnosed with breast cancer.

“With the advances in panel testing for predisposition genes, the likelihood of identifying a pathogenic or likely pathogenic mutation are higher—around 8% to 10% in these studies,” said Dr. Boughey. “However, we must remember that not all mutations are medically actionable. When evaluating genetic testing, we should consider the likelihood of identifying a mutation, cost of testing, and potential impact of the result on medical management. These studies provide data to consider broadening the indications for genetic testing.”

DISCLOSURE: Dr. Boughey reported no conflicts of interest.

Related Articles

Studies Challenge Relevance of Genetic Testing Guidelines for Breast Cancer

NEW RESEARCH suggests that current genetic testing guidelines for breast cancer are far too restrictive, excluding nearly half of high-risk patients. According to a pair of studies presented at the 2018 American Society of Breast Surgeons (ASBrS) Annual Meeting, women with breast cancer who did not ...




By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.